© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Alpha Cognition Inc (ACOG) stock remained unchanged at $8.90 a share on NASDAQ. The stock opened at $9.12, fluctuating between $8.72 to $9.30 during the session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | 8.99 | 9.30 | 8.65 | 8.90 | 85.33K |
| Sep 10, 2026 | 8.93 | 9.34 | 8.86 | 8.90 | 82.18K |
| Sep 09, 2026 | 9.54 | 9.54 | 8.91 | 9.13 | 58K |
| Sep 08, 2026 | 9.31 | 9.75 | 9.15 | 9.52 | 85.39K |
| Sep 04, 2026 | 9.22 | 9.54 | 9.10 | 9.52 | 45.94K |
| Sep 03, 2026 | 9.35 | 9.41 | 9.01 | 9.21 | 90.8K |
| Sep 02, 2026 | 9.17 | 9.42 | 9.06 | 9.32 | 55.6K |
| Sep 01, 2026 | 9.24 | 9.48 | 8.92 | 9.17 | 171.31K |
| Aug 31, 2026 | 9.20 | 9.37 | 9.00 | 9.27 | 215.62K |
| Aug 28, 2026 | 9.65 | 9.81 | 9.04 | 9.16 | 137.19K |
| Aug 27, 2026 | 9.38 | 10.01 | 9.38 | 9.74 | 155.57K |
| Aug 26, 2026 | 9.65 | 9.65 | 9.16 | 9.41 | 251.84K |
| Aug 25, 2026 | 9.80 | 9.87 | 9.39 | 9.75 | 220.14K |
| Aug 24, 2026 | 9.72 | 10.14 | 9.34 | 9.75 | 168.41K |
| Aug 21, 2026 | 9.62 | 10.10 | 9.36 | 9.75 | 294.25K |
| Aug 20, 2026 | 9.19 | 9.95 | 8.90 | 9.50 | 360.13K |
| Aug 19, 2026 | 8.71 | 9.26 | 8.53 | 8.89 | 140.15K |
| Aug 18, 2026 | 8.86 | 9.10 | 8.46 | 8.57 | 135.69K |
| Aug 17, 2026 | 8.89 | 9.00 | 8.20 | 8.84 | 367.19K |
| Aug 14, 2026 | 9.34 | 9.50 | 8.20 | 8.84 | 247.59K |
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
| Employees | 71 |
| Beta | 2.23 |
| Sales or Revenue | N/A |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |